Drug intelligence / Profile preview

chloroquine + sulfadoxine + pyrimethamine + LLIN

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Oral (for Chloroquine, Sulfadoxine, Pyrimethamine), Topical/environmental (llin)
01

Overview

This item represents a **combination strategy** for malaria control and prevention, involving three **pharmaceutical agents**—**chloroquine**, **sulfadoxine**, and **pyrimethamine**—combined with a **long-lasting insecticidal net** (LLIN), a **non-pharmaceutical intervention**. The three drugs are traditional antimalarial agents: chloroquine is a 4-aminoquinoline antimalarial effective by interfering with heme polymerization in Plasmodium species; sulfadoxine is a sulfonamide that inhibits dihydropteroate synthase (inhibiting folate synthesis); and pyrimethamine is a dihydrofolate reductase inhibitor targeting the same biosynthetic pathway at a different step[1][4]. Together, sulfadoxine-pyrimethamine exert a synergistic antimalarial effect via sequential blockade of folate synthesis, while chloroquine disrupts hemoglobin digestion in the parasite. LLINs provide a physical and chemical barrier to reduce mosquito bites, interrupting malaria transmission. This multi-pronged approach is used particularly in regions with drug resistance and high malaria burden, often as an interim or adjunct public health measure[2][5][8].

Other names
chloroquine, sulphadoxine pyrimethamine, LLINchloroquine + sulphadoxine + pyrimethamine + LLIN-University of Melbourne-malaria-sexually transmitted infections-anemia
02

Targets

DHFR (Dihydrofolate reductase)β-HematinDHPS (Dihydropteroate synthase)

Beyond the preview

Go deeper on chloroquine + sulfadoxine + pyrimethamine + LLIN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chloroquine + sulfadoxine + pyrimethamine + LLIN.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call